Pfizer and Valneva Join Forces on Lyme Disease Vaccine
The engineered protein vaccine VLA15 induces multiple antibodies in a Phase II trial and has the potential to provide protection against the different bacteria that cause Lyme disease in North America and Europe.
4 min readAug 21, 2020
